Journal of the American Heart Association
Dapagliflozin may help frail patients more after valve replacement
In frail patients, dapagliflozin was linked to lower relative risk of death or worsening heart failure versus controls at one year (hazard ratio 0.53).In frail patients, dapagliflozin was linked to lower relative risk of death or worsening heart failure versus controls at one year (hazard ratio 0.53).
Study of 1,222 patients undergoing transcatheter aortic valve implantation, against frail controlsDapagliflozin
Limit: Frailty subgroups were analysed after the fact, so the apparent extra benefit needs confirmation